NCT01409161 2025-12-17
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
47 trialsNCT06778187 2025-06-10
Oral-ATO for TP53-mutated Myeloid Malignancies
The University of Hong Kong
Phase 2 Recruiting
NCT03503864 2025-05-21
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT06933394 2025-04-18
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT04793919 2024-04-15
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 2 Recruiting
NCT06088030 2024-01-03
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT03624270 2022-10-04
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
The University of Hong Kong
Phase 2 Unknown
NCT01404949 2021-11-30
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02190695 2021-05-19
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Fox Chase Cancer Center
Phase 2 Completed
NCT04869475 2021-05-13
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
Ruijin Hospital
Phase 2 Unknown
NCT01470248 2021-02-17
Study of Arsenic Trioxide in Small Cell Lung Cancer
Emory University
Phase 2 Completed
NCT04695223 2021-01-06
Arsenic Trioxide for Structural p53 Mutations
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT00274820 2020-07-27
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00413166 2019-05-07
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00006091 2018-11-14
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00004149 2018-08-17
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Albert Einstein College of Medicine
Phase 2 Completed
NCT00104806 2018-08-10
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01835288 2018-05-21
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 2 Withdrawn
NCT00118196 2018-05-11
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Medical University of South Carolina
Phase 2 Terminated
NCT03381781 2018-01-04
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Ruijin Hospital
Phase 2 Unknown
NCT01428128 2017-12-13
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01184053 2017-06-14
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00128596 2017-04-27
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
University of Pittsburgh
Phase 2 Completed
NCT02956772 2017-02-23
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Hunan Provincial People's Hospital
Phase 2 Unknown
NCT00582400 2016-02-19
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
The University of Texas Medical Branch, Galveston
Phase 2 Terminated
NCT00528450 2016-01-29
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00024258 2015-11-25
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00670150 2015-10-27
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
University of Southern California
Phase 2 Withdrawn
NCT00075413 2015-10-02
Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer
The University of Texas Medical Branch, Galveston
Phase 2 Withdrawn
NCT00274781 2015-07-10
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
The Cleveland Clinic
Phase 2 Completed
NCT00201695 2015-06-10
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00184054 2014-07-25
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
University of Southern California
Phase 2 Terminated
NCT00276601 2014-04-17
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00053222 2013-09-05
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
University of Chicago
Phase 2 Completed
NCT00005040 2013-06-19
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005069 2013-06-19
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00075426 2013-02-12
Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The University of Texas Medical Branch, Galveston
Phase 2 Completed
NCT00016159 2013-01-16
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00006090 2012-10-10
Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00006092 2012-09-26
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00005595 2012-06-11
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease
Northwestern University
Phase 2 Terminated
NCT00005795 2012-06-11
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
Northwestern University
Phase 2 Completed
NCT00227682 2012-05-28
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00250042 2011-09-20
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT00193518 2011-05-03
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00850304 2009-02-24
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
Tehran University of Medical Sciences
Phase 2 Completed
NCT00193544 2009-01-23
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Completed